Serial entrepreneur and one of the most recognizable figures in Europe’s tech scene, Martín Varsavsky, has launched Prelude startup with $200 million in funding. The comprehensive fertility company focused on providing proactive fertility care to improve people’s chances of having healthy babies when they’re ready.
The fertility care provider with a particular focus on those looking to delay childbirth, says it “aims to give people more reproductive choices and control over their biological clocks” through egg and sperm freezing, genetic testing, embryo creation and single-embryo transfer.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
After founding 8 succsseful companies worldwide, including Urban Capital, Medicorp Sciences, Viatel, Jazztel, EINSTEINet, Ya.com, Eolia and FON, Varsavsky, launched the company today in participation of Lee Equity Partners, Reproductive Biology Associates (RBA), and My Egg Bank North America (MEB).
With more people delaying childbirth until their 30s and 40s to complete their education, pursue careers or find the right partner, Prelude aims to give people more reproductive choices and control over their biological clocks using The Prelude Method according to press release.
The Prelude Method is a four-step process that includes egg and sperm freezing, genetic testing, embryo creation and single-embryo transfer.
Currently, around 18% of women never get to have a baby, and another 20% have just one baby when they wanted more. By coupling earlier decision making with the latest reproductive science and technology, The Prelude Method can dramatically increase the probability of having a healthy baby and decrease the chances of requiring infertility therapy later in life.
Prelude has teamed with fertility industry leaders. RBA is led by reproductive endocrinologists Andrew A. Toledo, M.D., Daniel B. Shapiro, M.D., and Zsolt Peter Nagy, PhD (embryology).
Dr. Nagy and his team most recently contributed to significant improvements in oocyte cryopreservation using vitrification technology, which led to the establishment of the first highly efficient donor egg cryobank in the United States, My Egg Bank North America.
Dr. Nagy was also employed as a medical scientist on the team that first developed intracytoplasmic sperm injection, a novel insemination method now utilized worldwide.
“Prelude is using vitrification and genetic testing of embryos to dramatically improve pregnancy outcomes, ” said Nagy. “The Prelude Method helps us advance My Egg Bank’s mission to ensure people achieve their parenting dreams by literally freezing their fertility at its prime, instead of having to solve the issue of infertility later in life.”
READ MORE: Forbes, “End of the Biological Clock, ” by Miguel Helft / Feature on Martin Varsavsky and the Prelude Launch
